Recursion Pharmaceuticals/$RXRX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Ticker
$RXRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
800
Website
RXRX Metrics
BasicAdvanced
$2.8B
-
-$1.82
0.83
-
Price and volume
Market cap
$2.8B
Beta
0.83
52-week high
$12.36
52-week low
$3.79
Average daily volume
32M
Financial strength
Current ratio
4.114
Quick ratio
3.85
Long term debt to equity
7.76
Total debt to equity
9.948
Interest coverage (TTM)
-278.66%
Profitability
EBITDA (TTM)
-525.584
Gross margin (TTM)
-623.19%
Net profit margin (TTM)
-961.32%
Operating margin (TTM)
-960.08%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-38.51%
Return on equity (TTM)
-86.10%
Valuation
Price to revenue (TTM)
34.289
Price to book
2.82
Price to tangible book (TTM)
5.99
Price to free cash flow (TTM)
-5.112
Free cash flow yield (TTM)
-19.56%
Free cash flow per share (TTM)
-126.96%
Growth
Revenue change (TTM)
29.32%
Earnings per share change (TTM)
12.50%
3-year revenue growth (CAGR)
66.52%
3-year earnings per share growth (CAGR)
11.72%
What the Analysts think about RXRX
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
Bulls say / Bears say
Recursion Pharmaceuticals' acquisition of Exscientia for $688 million is expected to enhance its AI-driven drug discovery capabilities, potentially accelerating the development of new treatments. (reuters.com)
The rising costs of drug development, averaging $2.2 billion for new programs, position Recursion's AI platform as a cost-effective solution for pharmaceutical companies seeking to reduce expenses and expedite drug discovery. (fool.com)
Increasing adoption of AI in drug development, with major pharmaceutical companies collaborating with AI-driven firms like Recursion, indicates a growing market for Recursion's services and potential revenue growth. (fool.com)
Recursion's experimental drug REC-994 showed mixed results in a mid-stage study for treating cerebral cavernous malformation, leading to a 14% drop in share price and raising concerns about the drug's future prospects. (reuters.com)
The company's net loss increased to $235 million for the nine months ended September 30, 2023, compared to $182 million in the same period in 2022, indicating escalating operational expenses and financial strain. (ft.com)
Recursion's cash and cash equivalents decreased from $549 million at the end of 2022 to $387 million by September 30, 2023, suggesting a significant cash burn rate that may necessitate additional financing. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RXRX Financial Performance
Revenues and expenses
RXRX Earnings Performance
Company profitability
RXRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.8B as of July 28, 2025.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of July 28, 2025.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.